Anaptysbio Inc SEC Filings

AnaptysBio, Inc. reported that its Board of Directors authorized an amendment to its Stock Repurchase Plan, allowing the company to repurchase up to an additional $100.0 million of its outstanding common stock. This expands the capital return program beyond the existing authorization.

As of November 20, 2025, $6.4 million remained available under the current $75.0 million Stock Repurchase Plan. The company has already repurchased 3,443,188 shares of common stock, representing 11.2% of shares outstanding before the start of the plan, signaling a significant reduction in its share count over time.

AnaptysBio filed an 8-K noting two communications updates. The company furnished an updated corporate investor presentation as Exhibit 99.1 under Item 7.01 (Regulation FD), which is not deemed “filed” under the Exchange Act. It also filed a press release as Exhibit 99.2 under Item 8.01 announcing top-line Phase 2 data in ulcerative colitis for rosnilimab.

The filing lists Exhibits 99.1 (November 2025 presentation), 99.2 (press release dated November 10, 2025), and 104 (cover page XBRL). No financial results or transactional terms are included in this excerpt.

AnaptysBio (ANAB) reported stronger Q3 results and outlined a potential separation. For the three months ended September 30, 2025, collaboration revenue reached $76.3 million, driven by GSK-related royalties and milestones, while operating expenses were $41.6 million. Income from operations was $34.7 million, and net income was $15.1 million (diluted EPS $0.52).

The company recognized a $50.0 million Jemperli sales milestone in Q3 and recorded royalty revenue of $26.3 million. Non‑cash interest expense tied to royalty monetizations was $22.5 million in Q3. Cash and cash equivalents were $109.8 million, with short‑term investments of $139.1 million. A liability related to the sale of future royalties totaled $331.8 million, and stockholders’ equity stood at a $29.4 million deficit. The company repurchased 3.34 million shares for $65.2 million, leaving $9.8 million authorized.

Strategically, the Board approved exploring a separation into two public companies: one focused on managing GSK/Vanda milestones and royalties, and another advancing immunology programs including rosnilimab, ANB033 and ANB101, with completion targeted by year‑end 2026, subject to approvals.

AnaptysBio (ANAB) furnished an 8-K announcing it issued a press release with financial results for the three and nine months ended September 30, 2025. The release is attached as Exhibit 99.1 dated November 4, 2025.

The Item 2.02 information, including Exhibit 99.1, is furnished and not deemed “filed” and is not incorporated by reference except as expressly stated in future filings. An inline XBRL cover page is included as Exhibit 104.

AnaptysBio, Inc. (ANAB) filed a Form 8-K announcing that on October 14, 2025 it will host a conference call to discuss ANB033 and use a slide presentation during the call. The company also updated its corporate investor presentation on the same date.

Both presentations are furnished under Regulation FD as Exhibits 99.1 and 99.2 and, as stated, shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or incorporated by reference except as expressly set forth by specific reference.

Eric J. Loumeau, Chief Legal Officer of AnaptysBio, Inc. (ANAB), reported both purchases and sales of company common stock on 09/30/2025. He acquired 5,000 shares by exercising employee stock options at an exercise price of $14.02 and an additional 1,325 shares under the company ESPP included in the reported holdings, bringing his post-transaction direct ownership to 17,328 shares. He also sold 8,240 shares at $29.00 per share under a 10b5-1 trading plan adopted April 11, 2025.

The Form 4 shows he retains outstanding options to purchase 68,000 shares exercisable under the option described and additional unvested options aggregating up to 422,310 shares that vest per their terms. Transactions were routine insider activity documented under Section 16 reporting rules.

Form 144 notice for ANAPTYSBIO, Inc. (ANAB) shows a proposed sale of 8,240 common shares totaling an aggregate market value of $238,960.00. The sale is reported through Morgan Stanley Smith Barney LLC on the NASDAQ with an approximate sale date of 09/30/2025. The securities were acquired in two transactions: 3,240 restricted shares issued on 01/06/2024 (paid at issuance) and 5,000 shares from a stock option exercise on 09/30/2025 (paid in cash). No securities of the issuer were sold by the reporting person in the prior three months, and the filer represents no undisclosed material adverse information.

AnaptysBio's board has approved plans to explore separating its business into two independent, publicly traded companies. The company says the separation is expected to occur by the end of 2026. Management will host a conference call using a slide presentation to discuss the potential separation; the presentation is included as an exhibit. A press release describing the board action is also attached as an exhibit. The disclosure notes that the Item 7.01 information and the presentation are not deemed "filed" for Section 18 purposes.